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ABBREVIATIONS 
OSAS: obstructive sleep apnoea syndrome; CPAP: continuous positive air pressure;  
AHI: apnoea/hypopnoea index; MACCE: major cardiovascular and cerebrovascular event  
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SUMMARY 
Background 
Continuous positive airway pressure therapy (CPAP) is a highly effective treatment for obstructive sleep 
apnoea syndrome (OSAS). However, poor adherence is a limiting factor and a significant proportion of 
patients are unable to tolerate CPAP. Aim of this study was to determine predictors of long-term non-
compliance with CPAP. 
Methods 
CPAP treatment was prescribed to all consecutive patients with moderate or severe OSAS (AHI ≥15 
events/h) (n=295) who underwent a full-night CPAP titration study at home between February 1, 2002 and 
December 1, 2016. Adherence was defined as CPAP use for at least 4 hours per night and 5 days per week. 
Subjects had periodical follow-up visits including clinical and biochemical evaluation and assessment of 
adherence to CPAP.  
Results 
Median follow-up observation was 74.8 (24.2/110.9) months. The percentage of OSA patients adhering to 
CPAP was 41.4% (42.3% in males and 37.0% in females) and prevalence was significantly higher in severe 
OSAS as compared to moderate (51.8% vs 22.1%; p<0.001; respectively). At multivariate analysis, lower 
severity of OSAS (HR=0.66; CI95 0.46-0.94) p<0.023), cigarette smoking (HR=1.72; CI95 1.13-2.61); p=0.011) 
and previous cardiovascular events (HR=1.95; CI95 1.03-3.70; p=0.04) were the only independent 
predictors of long-term non-adherence to CPAP after controlling for age, gender and metabolic syndrome. 
Conclusions 
in our cohort of patients with moderate/severe OSAS who were prescribed CPAP therapy, long-term 
compliance to treatment was present in less than half of the patients. Adherence was positively associated 
with OSAS severity and negatively associated with cigarette smoking and previous cardiovascular events at 
baseline. 
 
KEY WORDS 
Obstructive sleep apnoea syndrome; continuous positive air pressure; adherence to treatment;  
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1. INTRODUCTION 
Obstructive Sleep Apnoea (OSA) is a disorder characterized by daytime sleepiness and repeated breathing 
cessations during sleep, which can result in cycles of hypoxia, negative intrathoracic pressure and arousals 
with potentially serious cardiovascular consequences [1-5]. 
Continuous positive airway pressure therapy (CPAP) is a highly effective treatment for OSA and should be 
considered both first-line and gold-standard treatment for patients with all stages of OSAS [6-8]. CPAP 
improves quality of life and excessive daytime sleepiness and decreases sympathetic neural activity and 
blood pressure. Besides, the prescription of CPAP appears to reduce long-term CVD events[9] and total 
mortality, although negative results have been also reported  and not all patients benefit from CPAP 
treatment even if they have a severe OSA  [10, 11]. 
Adequate CPAP compliance is essential for achieving cardiovascular and metabolic benefits in patients with 
OSAS.  However, poor adherence to CPAP is a significant limiting factor in treating OSA despite efforts to 
improve devices and educate patients especially during the early stages of treatment. In fact, failure to 
comply with CPAP therapy may occur in up to 25% to 50% patients with OSA and patient adherence to 
treatment frequently remains inadequate[12, 13].  A significant proportion of patients are unable to 
tolerate CPAP therapy, and frequently seek alternate treatment. A recent systematic literature review 
reported that the rate of CPAP adherence remained persistently low over twenty years of published 
data[14]. 
Various factors were evaluated in trying to predict compliance [15]. Some patients may refuse treatment 
without even initiating it, some eventually abandon therapy. Poor mask fit and discomfort, complaints of 
noise, interference with normal life and sexual functioning frequently induce low adherence. In fact, CPAP 
may induce nasal drying, congestion, rhinorrhea, sinusitis, and allergic reaction to the materials in the 
mask. Besides, the patient’s age, gender, low socioeconomic status, overweight, obesity, comorbid 
conditions and smoking have been associated to poor compliance. By contrast, patients with a more severe 
OSA tend to be more compliant and their apnoea-hypopnea index (AHI) showed a relationship with 
improved compliance[16]. In particular, the balance between symptom severity pre-treatment and 
symptom relief with CPAP treatment is amongst the strongest predictors of CPAP compliance.  
However, so far, no single factor has been consistently identified as predictive of adherence. Moreover, 
there are very few data on objectively assessed compliance with CPAP in large OSA cohorts and treatment 
adherence has been incompletely assessed in long-term follow-up studies. 
Aim of this study was to determine predictors of long-term non-compliance with CPAP in a large cohort of 
moderate and severe newly diagnosed OSA patients during a six-year follow-up. 
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2. MATERIAL AND METHODS 
2,1 Subjects 
The initial population consisted of 483 patients who attended consecutively our outpatient metabolic clinic 
because of suspected metabolic disorders with heavy snoring and possible OSAS between February 1, 2002 
and December 1, 2016.  Patients had a complete clinical and biochemical work-up including unattended 
overnight home polysomnography. The device recorded nasal and oral airflow, chest and abdominal 
movement, pulse oximetry, body position and snoring noise. The sleep recordings were downloaded to a 
computer and scored by a principal investigator. OSAS severity was quantified as the number of 
apnea/hypopnea events/h during sleep study (AHI).  Patients were categorized as follows; snorers without 
OSAS with AHI <5 events/h; mild OSA with AHI 5-14 events/h; moderate/severe OSA with AHI ≥15 events/h.  
Information on previous cardiovascular and cerebrovascular disease (MACCE) defined as history of 
physician-diagnosed heart failure, angina, myocardial infarction, stroke and coronary revascularization, was 
obtained for each participant. Finally, all the therapies and the number of tablets consumed every day were 
recorded. A detailed description of screening procedures was previously reported[17, 18]. 
CPAP treatment was prescribed to all consecutive patients with moderate or severe OSAS (AHI ≥15 
events/h) (n=301) who underwent a full-night CPAP titration study at home using an automated pressure 
setting device. Written consent was obtained from all subjects before the study and the study conforms to 
the ethical guidelines of the 1975 Declaration of Helsinki. The research protocol was approved by the 
University Department of Experimental Medicine and Pathology scientific board in 2002. 
 
2.2 Assessment of compliance to CPAP 
Adherence to CPAP was arbitrarily defined as CPAP use for at least 4 hours per night and 5 days per week, 
although there is no definite agreement on frequency and duration of optimal CPAP treatment.  Subjects 
had periodical follow up visits including clinical and biochemical evaluation and assessment of adherence to 
CPAP. Besides, patients were contacted by telephone by a single investigator who was not part of the 
clinical team between December 1, 2016 and May 31, 2017. First, they were questioned if they started 
treatment and were still using their CPAP device. Those adhering to therapy were asked to estimate the 
number of nights per week, and hours per night CPAP was being used. Those who abandoned therapy and 
those who never initiated treatment were questioned about their reasons for non-adherence. 
2.3 Statistical analysis 
Continuous variables are reported as mean + standard deviation or median with interquartile range. 
Continuous variables were analyzed by Student’s t-test or Mann-Whitney test depending on their 
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distribution.   Dichotomous variables are reported as numbers and percentages.  Differences were tested 
using the χ2 test for categorical variables. All tests were two-tailed and only p values <0.05 were considered 
as statistically significant. Univariate and multivariate Cox regression analyses using a forward selection was 
used to calculate the unadjusted and adjusted relative hazard ratios (HR) of predictors for discontinuation 
of CPAP therapy. Analyses were carried out with SPSS V.18.0 (Armonk, USA). 
 
3. RESULTS 
Complete information on CPAP compliance was available for 301 subjects with moderate or severe OSA. 
Median follow-up observation was 74.8 (24.2/110.9) months. The percentage of OSA patients adhering to 
CPAP was 41.4% (42.3% in males and 37.0% in females) and prevalence was significantly higher in severe 
OSAS as compared to moderate OSAS (51.8% vs 22.1%; p<0.001; respectively). Severe OSAS had a better 
compliance than moderate both in males (53.4% vs 20.0%; p<0.001; respectively) and females (43.3% vs 
29.2%; p=0.39, respectively). Adherers and non-adherers had similar age at the time of diagnosis of OSA 
(57.1 + 10.5 years vs 57.0 + 10.9 years, respectively). 
Clinical and biochemical characteristics of adherers and non-adherers are reported in Table 1. At baseline 
examination, the indices of OSA severity – AHI and ODI- were significantly increased, while SatO2 was 
decreased in patients with good compliance. In the same group, the indexes of central obesity and serum 
triglycerides tended to be higher. Prevalence of cigarette smokers was about double in non-adherers as 
compared to adherers (20.8% vs 10.7%; p=0.026, respectively). No statistically significant differences were 
observed for the prevalence of diabetes, arterial hypertension, metabolic syndrome, statin use and 
previous MACCE at the basal examination. 
Table 2 reports the results of univariate and multivariate Cox regression analyses of predictors of CPAP 
discontinuation.  In the Cox analysis adjusted for possible confounders, lower severity of OSAS (HR=0.66; 
CI95 0.46-0.94) p<0.023), cigarette smoking (HR=1.72; CI95 1.13-2.61); p=0.011) and previous MACCE 
(HR=1.95; CI95 1.03-3.70; p=0.04) were the only independent predictors of long-term non-adherence to 
CPAP after controlling for age, gender and metabolic syndrome. 
The main reasons for poor adherence were self-reported mask-related and pressure-related side effects, 
nasal symptoms, and psychological and social factors. Other frequent reasons for stopping treatment were 
surgical management or weight loss with consequent improvement of OSA.  
4. DISCUSSION 
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There are few data on the long-term assessment of adherence to CPAP in OSAS patients and no single 
factor so far, has been consistently identified as predictive of long-term adherence. Moreover, studies on 
CPAP adherence in Mediterranean countries are limited. 
In this study, about 40% of patients with moderate or severe OSAS, who were prescribed CPAP therapy, 
were still on treatment after an average six-year follow-up observation when non-adherence was defined 
as a mean of ≤4 hours of use per night and 5 days per week. This is in agreement with previous studies 
showing a compliance to treatment in about 30-80% of patients depending on the definition criteria for 
adherence and the duration of follow-up [12, 13]. 
Compliance was higher in patients with more severe OSAS, where half of those with AHI >30 events/hour 
were good adherers to CPAP treatment.  Those with a higher AHI tended to be more compliant both in 
males and females and in all ages. 
Our findings are in keeping with the results of some studies reporting a strong relationship between 
adherence to CPAP and the severity of sleep-disordered breathing. So, in a large prospective study 
performed in US, disease severity rather than patients' symptoms or complaints, seemed to play a role in 
the quality of compliance to treatment[19]. Moreover, in a large cohort of OSAS patients, severity of sleep-
disorder breathing assessed as number of oxygen desaturation events, was the only clinical condition 
associated to long-term adherence[20]. Similar findings were reported in a retrospective chart review of 
369 patients with moderate or severe OSAS who were recommended to receive CPAP: at one year, older 
male patients with higher AHI values were more adherent to CPAP[21]. In addition, a highly significant 
correlation of compliance with the initial AHI was found in a small study of OSA patients at 14 months on 
the average after starting treatment with CPAP[22]. Moreover, an association between compliance to 
treatment and severity of OSAS was also reported in a retrospective study evaluating 156 patients with 
OSAS were patients with a higher AHI were those who better adhered to long-term treatment with 
CPAP[23]. Finally, in a cross-sectional study of 138 OSA patients performed in Lebanon, higher oxygen 
desaturation index at baseline was associated with a better short-term CPAP adherence [24]. 
Based on these data, it could be speculated that patients with more severe OSAS have a better compliance.  
However, other studies showed that measures of OSA severity per se appear poorly associated with CPAP. 
In fact, in a short-term study of 59 patients (42 men) with metabolic syndrome and OSA, mask leak was the 
only independent predictor of CPAP compliance at the 8-week follow-up visit [25]. Moreover, in another 
study of 60 patients who were recommended CPAP therapy, one-year compliance was associated with 
higher body mass index, higher Epworth sleepiness scale score, history of witnessed apnea, and reduction 
in daytime sleepiness with CPAP therapy, while OSAS severity was not associated [26]. In conclusion, based 
on the above data, it is difficult to conclude that the severity of OSA at the initial sleep study always 
predicts long-term use of CPAP. 
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In our study, cigarette smoking was an independent predictor of non-compliance to CPAP. This is in keeping 
with the results of an 8-years retrospective chart review of older male patients prescribed CPAP therapy for 
OSA, where cigarette smoking was associated with non-compliance [27]. However, these findings are in 
contrast with data from a small prospective cohort study where cigarette smoking, alcohol intake, 
concurrent medication use and work patterns were not important predictors of short-term CPAP use [28]. 
Previous MACCE in our study were independent predictors of worse adherence to CPAP. Similar findings 
have been reported in previous studies on the compliance to CPAP in patients with concomitant OSAS and 
cardiovascular disease, where adherence decreased progressively over time [29, 30]. These findings raise 
the possibility that patients with OSAS and CVD may benefit less from CPAP therapy as they are more 
concerned with cardiovascular disease. 
There are several strengths and limitations of this study that merit to be discussed. Major strength of this 
study is the duration of follow-up that is greater than that of most published studies. Unattended home 
polysomnography should be considered as a major limitation of this study, although an excellent 
correlation with the results of attended polysomnography has been reported [31]. A further limitation is 
that we used telephone survey to assess the compliance of CPAP therapy in half of the patients because 
almost all of the patients used CPAP units not capable to keep record of night use.  This may have ended 
with a possible selection bias since patients lie a lot when asked about compliance and there may 
be discrepancies between what patients think they do at night and what they really do  [32]. 
Moreover, the studied population was taken only from an outpatient metabolic clinic and non-
snorers and patients without metabolic disorders were probably not included in the study. Finally, 
CPAP compliance was not assessed in patients with mild OSAS. 
In summary, in our cohort of patients with moderate or severe OSAS who were prescribed CPAP therapy, 
long-term compliance to treatment was present in less than half of the patients. Adherence was positively 
associated with severity of OSAS and negatively associated with cigarette smoking and previous MACCE at 
the initial examination. 
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Table 1. Clinical and biochemical characteristics of adherers and non-adherers to CPAP therapy 
 
 
Non-adherers  
to CPAP 
(n=178) 
Adherers  
to CPAP 
(n=123) 
p 
Age (yrs) 57.0 ± 10.5 57.1 ± 10.9 0.944 
AHI (events/h) 37.6 ± 20.4 45.7 ± 17.6 0.001 
ODI (events/h) 34.7 ± 22.4 45.6 ± 21.3 0.000 
Average SatO2 (%) 92.3 ± 3.6 90.3 ± 7.8 0.007 
BMI (kg/m2) 32.9 ± 6.0 34.4 ± 8.8 0.099 
Waist circumference (cm) 113.0 ± 13.6 116.2 ± 12.9 0.052 
Hip circumference (cm) 114.2 ± 12.1 117.7 ± 11.9 0.022 
Systolic blood pressure (mmHg) 135 ± 15 135 ± 15 0.455 
Diastolic blood pressure (mmHg) 84 ± 10 83 ± 10 0.562 
Total Cholesterol (mg/dl) 206.2 ± 42.3 196.7 ± 42.5 0.067 
HDL Cholesterol (mg/dl) 45.7 ± 12.0 42.2 ± 9.9 0.012 
LDL Cholesterol (mg/dl) 129.0 ± 35.8 121.1 ± 40.5 0.088 
Triglycerides (mg/dl) 130.0 (92.0/180.0) 148.0 (102.5/205.0) 0.107 
Fasting blood glucose (mg/dl) 103.4 ± 27.0 104.0 ± 26.1 0.835 
Insulin (µU/ml) 20.9 ± 17.5 21.7 ± 16.9 0.748 
HOMA-IR 3.9 ± 4.8 4.0 ± 5.5 0.831 
Diabetes (%) 18.1 20.3 0.648 
Hypertension (%) 69.1 73.0 0.513 
Metabolic syndrome (%) 61.3 71.2 0.099 
Cigarette smoking (%) 20.8 10.7 0.026 
Statin use (%) 38.6 45.7 0.262 
Polypharmacy (n. of pills/day) 2.5 (1.0/5.0) 4.0 (2.0/6.0) 0.001 
Previous MACCE (%) 13.0 10.1 0.274 
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Table 2. Univariate and multivariate Cox regression analysis of predictors of CPAP discontinuation 
 
 Univariate Analysis Multivariate Analysis 
 HR (C.I. for HR) p HR (C.I. for HR) p 
Age (yrs) 1.007 (0.993-1.021) 0.331 1.008 (0.992-1.025) 0.331 
Female gender 1.123 (0.762-1.656) 0.558 1.050 (0.664-1.661) 0.835 
AHI (events/h) 0.989 (0.981-0.997) 0.007   
ODI (events/h) 0.993 (0.986-1.001) 0.081   
Average SatO2 (%) 1.014 (0.975-1.055) 0.480   
Severe OSAS (%) 0.630 (0.461-0.862) 0.004 0.661 (0.463-0.945) 0.023 
BMI (kg/m2) 0.989 (0.962-1.016) 0.428   
Waist circumference 
(cm) 0.994 (0.982-1.006) 0.322   
Hip circumference (cm) 0.995 (0.982-1.009) 0.501   
Systolic blood pressure 
(mmHg) 0.992 (0.982-1.002) 0.134   
Diastolic blood pressure 
(mmHg) 0.987 (0.971-1.002) 0.093   
Total Cholesterol (mg/dl) 1.001 (0.997-1.004) 0.770   
HDL Cholesterol (mg/dl) 1.016 (1.003-1.030) 0.019   
LDL Cholesterol (mg/dl) 0.999 (0.995-1.003) 0.557   
Triglycerides (mg/dl) 1.000 (0.998-1.002) 0.991   
Fasting blood glucose 
(mg/dl) 1.001 (0.994-1.007) 0.868   
Insulin (µU/ml) 0.999 (0.990-1.007) 0.757   
Diabetes (%) 0.913 (0.610-1.367) 0.659   
Hypertension (%) 1.153 (0.801-1.659) 0.443   
Metabolic Syndrome (%) 0.802 (0.581-1.109) 0.182 0.757 (0.531-1.080) 0.125 
Cigarette smoking (%) 1.655 (1.119-2.447) 0.012 1.723(1.133-2.619) 0.011 
Statin use (%) 0.979 (0.698-1.372) 0.901   
Polypharmacy (n. of 
pills/day) 1.000 (0.938-1.066) 0.995   
Previous MACCE (%) 1.889 (1.114-3.204) 0.018 1.954 (1.030-3.705) 0.040 
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HIGHLIGHTS 
 
• CPAP is an effective treatment for obstructive sleep apnoea. 
• Poor adherence to CPAP is a significant limiting factor in treating OSA 
• Aim of this study was to determine predictors of long-term non-compliance 
• Less than half of the patients were compliant during a six-year follow-up 
• Adherence was positively associated with OSA severity, smoking and previous CVD 
